Maravai Lifesciences Holdings, Inc. SEC filings MRVI
Maravai Lifesciences Holdings, Inc. has 425 filings in SEC EDGAR's recent list, going back to Sep 8, 2020. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K | Current report | Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, New debt, Regulation FD disclosure
|
Jun 3, 2026 | Jun 2, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 29, 2026 | May 26, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| 8-K |
Current report
Results of operations
|
Feb 25, 2026 | Feb 25, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Officer or director change
|
Oct 27, 2025 | Oct 21, 2025 |
| 8-K |
Current report
Results of operations, Exit or restructuring costs, Officer or director change
|
Aug 11, 2025 | Aug 7, 2025 |
| 8-K |
Current report
Auditor change
|
Jul 18, 2025 | Jul 16, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 25, 2025 | Jun 22, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 9, 2025 | Jun 8, 2025 |
| 8-K |
Current report
Shareholder vote results
|
May 28, 2025 | May 22, 2025 |
| 8-K |
Current report
Results of operations
|
May 12, 2025 | May 12, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 20, 2025 | Mar 20, 2025 |
| 8-K |
Current report
Results of operations, Restatement
|
Mar 18, 2025 | Mar 17, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Feb 25, 2025 | Feb 25, 2025 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Jan 8, 2025 | Jan 2, 2025 |
| 8-K |
Current report
Other events
|
Dec 18, 2024 | Dec 18, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 5, 2024 | Dec 3, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2024 | Nov 7, 2024 |
| 8-K |
Current report
Material agreement
|
Sep 12, 2024 | Sep 10, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2024 | Aug 7, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 29, 2024 | Jul 23, 2024 |
| 8-K |
Current report
Officer or director change
|
Jun 12, 2024 | Jun 10, 2024 |
| 8-K |
Current report
Shareholder vote results
|
May 28, 2024 | May 23, 2024 |
| 8-K |
Current report
Results of operations
|
May 8, 2024 | May 8, 2024 |
| 8-K |
Current report
Results of operations
|
Feb 22, 2024 | Feb 22, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2023 | Nov 7, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2023 | Aug 7, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 27, 2023 | Jul 27, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 20, 2023 | Jul 19, 2023 |
| 8-K |
Current report
Shareholder vote results
|
May 22, 2023 | May 18, 2023 |
| 8-K |
Current report
Results of operations
|
May 8, 2023 | May 8, 2023 |
| 8-K |
Current report
Officer or director change
|
Mar 13, 2023 | Mar 8, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 10, 2023 | Mar 10, 2023 |
| 8-K |
Current report
Results of operations
|
Feb 22, 2023 | Feb 22, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 1, 2022 | Dec 1, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 2, 2022 | Nov 2, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 19, 2022 | Oct 18, 2022 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 3, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2022 | Aug 4, 2022 |
| 8-K |
Current report
Shareholder vote results
|
May 16, 2022 | May 12, 2022 |
| 8-K |
Current report
Results of operations
|
May 5, 2022 | May 5, 2022 |
| 8-K |
Current report
Results of operations
|
Feb 23, 2022 | Feb 23, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 28, 2022 | Jan 28, 2022 |
| 8-K |
Current report
Material agreement
|
Jan 20, 2022 | Jan 19, 2022 |
| 8-K |
Current report
Other events
|
Jan 3, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2021 | Nov 10, 2021 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets
|
Sep 3, 2021 | Sep 2, 2021 |
| 8-K |
Current report
Material agreement, Results of operations
|
Aug 10, 2021 | Aug 5, 2021 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 20, 2021 | May 19, 2021 |
| 8-K |
Current report
Results of operations
|
May 10, 2021 | May 10, 2021 |
| 8-K |
Current report
Results of operations, Other events
|
Apr 5, 2021 | Apr 5, 2021 |
| 8-K |
Current report
Results of operations
|
Mar 2, 2021 | Mar 2, 2021 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights, Officer or director change, Bylaw or fiscal year change, Other events
|
Nov 25, 2020 | Nov 19, 2020 |
Showing 56 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MRVI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1823239
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.